Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in June 2019
August 2019
in “
Regenerative Medicine
”
New to Minoxidil? There is a guide in the encyclopedia. Read the guide → 
Studysummary In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations. Our plain-language summary of this paper — not a Tressless recommendation.
In June 2019, there were numerous advancements in stem cell research and regenerative medicine. Follica reported positive interim data from a study on male androgenetic alopecia, showing significant hair count improvement in 20 male participants. Minovia Therapeutics began a Phase I/II trial for Pearson syndrome with 7 pediatric patients, and the FDA granted several designations to their mitochondrial cell therapy. Triumvira Immunologics received approval for a Phase I/II study of TAC01-CD19, a T-cell therapy for B-cell malignancies. Kiadis Pharma acquired CytoSen Therapeutics to enhance cell-based cancer immunotherapy. GPB Scientific was awarded a $2.2 million NIH grant to improve cell separation technology, and InGeneron extended its Series D financing to $43 million for cell therapy programs. Additionally, various strategic collaborations, clinical trials, and regulatory designations were announced, reflecting significant progress in the field.
